{"prompt": "['Protocol', 'BioCryst Pharmaceuticals, Inc.', 'Version 6.0', 'CONFIDENTIAL', 'BCX7353-301 (APeX-J)', 'Unlikely:', 'The event does not follow a reasonable temporal sequence from drug', \"administration and is readily explained by the subject's clinical state or by\", 'other modes of therapy administered to the subject.', 'Possibly', 'There is some temporal relationship between the event and the administration', 'Related:', \"of the study drug and the event is unlikely to be explained by the subject's\", 'medical condition, other therapies, or accident.', 'Probably', 'The event follows a reasonable temporal sequence from drug administration,', 'Related:', 'abates upon discontinuation of the drug, and cannot be reasonably explained', \"by the known characteristics of the subject's clinical state.\", 'Definitely', 'The event follows a reasonable temporal sequence from study drug', 'Related:', 'administration, follows a known or suspected response pattern to the study', 'drug, is confirmed by improvement upon stopping the study drug', '(dechallenge), and reappears upon repeated exposure (rechallenge, if', 'rechallenge is medically appropriate).', '12.1.5.', 'Reporting Serious Adverse Events and Suspected Unexpected Serious Adverse', 'Reactions', 'Any SAE must be reported by phone or email to the sponsor medical monitor and via the AE and', \"SAE eCRFs within 24 hours of the investigator's awareness of the SAE. All additional follow-up\", 'evaluations of the SAE must be reported to BioCryst or its designee as soon as they are available', 'by amending these eCRFs. The SAE notification should be reported to:', 'Phone (24 hours): 1 919-859-7905', 'Email: safety@biocryst.com and mmj@biocryst.com', 'In the event the eCRF system is not functioning, the reporting of an SAE must not be delayed.', 'Sites will have SAE report forms (electronic Word document) that can be completed and emailed', 'to the above recipients. As soon as the eCRF system is functioning, that particular SAE must be', 'entered into the AE eCRF. The SAE eCRF for that particular event does not need to be', 'completed if the site communicates all follow-up on the separate SAE report form that was', 'initially completed. If the site wishes to enter follow-up information on the SAE via the SAE', 'eCRF, then the SAE eCRF must be completed with the initial as well as the follow-up', 'information.', 'Immediate reporting should allow BioCryst to take the appropriate measures to address potential', 'new risks in a clinical trial. Therefore, the initial report should be submitted by the investigator', 'within a very short period of time and under no circumstances should this period exceed 24 hours', 'following awareness of the SAE.', 'The follow-up report should allow BioCryst to determine whether the SAE requires a', 'reassessment of the benefit-risk profile of the study drug in a clinical trial, if the relevant', 'information was not already available and provided in the initial report.', 'Japan-specific rules and requirements for safety management will be described in the Safety and', 'Medical Management Plan prepared for the current protocol.', '87']['Protocol', 'BioCryst Pharmaceuticals, Inc.', 'Version 6.0', 'CONFIDENTIAL', 'BCX7353-301 (APeX-J)', 'BioCryst or its designee will submit all suspected unexpected serious adverse reaction (SUSAR)', 'reports (initial and follow-up) or other safety information (eg, revised IB) to the required', 'authorities.', 'BioCryst or its designee shall ensure that all relevant information about SUSARs that are fatal or', 'life-threatening is recorded and reported as soon as possible to the competent authorities in all', 'ICH regions, and to the institutional review boards (IRBs) or independent ethics committees', '(IECs), and in any case no later than 7 days after knowledge by BioCryst of such a case, in', 'accordance with all applicable local laws. All other SUSARs shall be reported to the competent', 'authorities concerned and to the IRBs/IECs concerned as soon as possible but within a maximum', 'of 15 days of first knowledge by BioCryst. BioCryst or designee shall also inform all', 'investigators. Investigators are responsible for retaining a copy in their files, unless otherwise', 'instructed.', '12.1.5.1. Reporting Adverse Events of Special Interest', 'All skin disorders or abnormal findings of the skin are adverse events and should be reported in', 'the usual manner on the eCRF as per Section 12.1.2. However, events of maculopapular rash', 'assessed as related to study drug/IMP, regardless of severity, are considered to be EOSIs which', 'require additional reporting. Any new maculo-papular rash assessed as related to the use of study', 'drug must be reported to the sponsor medical monitor via the eCRFs, specifically both the AE', \"eCRF and the SAE eCRF, within 24 hours of the investigator's assessment of the event.\", 'The SAE eCRF will also serve as an EOSI Report form, although the rash event itself may not', 'meet seriousness criteria. High resolution photographs must also be submitted via email as', 'described in Section 11.2.14. All additional follow-up evaluations of the event must be reported', 'to BioCryst or its designee as soon as they are available. The notification should be sent to the', 'following email addresses:', 'Phone (24 hours): +1 919-859-7905', 'Email: safety@biocryst.com and mmj@biocryst.com', 'In the event the eCRF system is not functioning, the reporting of an EOSI must not be delayed.', 'Sites will have SAE/EOSI Report forms (electronic Word document) that can be completed and', 'emailed to the above recipients. As soon as the eCRF is functioning, the EOSI must be entered', 'into the AE eCRF. The SAE eCRF for that particular event does not need to be completed if the', 'site communicates all follow-up on the separate SAE/EOSI Report form that was initially', 'completed. If the site wishes to enter follow-up information on the EOSI via the SAE eCRF, then', 'the SAE eCRF must be completed with the initial as well as the follow-up information.', 'This method of reporting should allow BioCryst to obtain more information including a full', 'clinical description and information regarding the evaluation. Therefore, the initial report and', 'photographs should be submitted by the investigator within a very short period of time and under', 'no circumstances should this period exceed 24 hours following assessment of the event.', 'The follow-up report should contain information about the clinical course, medical evaluation,', 'additional photographs (if relevant), biopsy (if done), and laboratory results.', '88']\n\n###\n\n", "completion": "END"}